Editorially reviewed · Last updated September 8, 2026 · How we review
Key findings
- The July 2026 advisory committee recommended BPC-157 for the 503A bulks list; its recommendation does not itself change the final list.
- FDA staff recommended against inclusion. The agency still has to decide how to proceed; no verified final-rule date is established.
- The FDA briefing identified older randomized studies available as meeting abstracts and several small published pilots. These do not establish effectiveness for injury recovery.
- Human safety and pharmacokinetic evidence remains limited, particularly for commonly marketed routes of administration.
- Research labels do not turn an unapproved product into an authorized human treatment.
BPC-157: The FDA 503A Vote, Legality, and What the Evidence Actually Shows
BPC-157 is not an FDA-approved drug. An advisory recommendation does not authorize a finished product or establish safety. FDA’s current linked 503A Category 1 document does not list BPC-157; a prescription or online listing is not proof of a qualifying compounding pathway.
That correction is the single most important thing to understand about this news, so this page leads with it — then covers what BPC-157 actually is, what the human evidence does and does not show, what commercial interest can and cannot tell us, and why the grey-market vials people are buying today carry real risk.
The FDA Vote: What Actually Happened
On July 23–24, 2026, the PCAC met to review seven peptides for possible inclusion on the 503A Bulks List. BPC-157 (both the free-base and acetate forms) was the first one voted on.
| Detail | What the record shows |
|---|---|
| Vote | 8 in favor, 6 against, 1 abstention |
| Body | FDA Pharmacy Compounding Advisory Committee (PCAC) |
| Date | July 23, 2026 |
| Question | Add BPC-157 to the 503A Bulks List for compounding? |
| Indication reviewed | Ulcerative colitis |
| FDA staff position | Recommended against — cited a general lack of quality human safety and efficacy data |
| Binding? | No — the vote is advisory only |
| Docket | BPC-157 first of 7 peptides reviewed July 23–24 |
The FDA briefing recommended against adding BPC-157-related substances, citing limitations in characterization, safety and efficacy evidence. The favorable vote was an advisory committee recommendation, not the agency reversing its scientific assessment.
Eligible Does Not Mean Legal
FDA evaluates list additions through rulemaking. Separately, some Category 1 substances fall within a conditional interim enforcement policy. The current linked category document, updated May 14, 2026, does not list BPC-157 in Category 1. Removal of a withdrawn nomination from a category is not a finding of safety or automatic inclusion elsewhere.
This review found no final FDA rule adding BPC-157 to the 503A Bulks List. It does not predict a 12–24-month deadline or determine the legality of a particular product or prescription.
Is BPC-157 Legal Right Now?
| Question | What the reviewed FDA record establishes |
|---|---|
| FDA-approved drug? | No |
| Did the advisory vote add it to the final 503A list? | No; a recommendation is non-binding |
| On the linked 503A Category 1 document? | Not listed in the May 14, 2026 document checked for this review |
| Does a prescription prove a product meets compounding requirements? | No; the applicable conditions must be satisfied |
| Known date for a final FDA decision? | No date established here |
Compounded drugs are not FDA-approved. A possible future list addition would not approve BPC-157 for injury recovery or validate a seller’s vial.
What Is BPC-157?
BPC-157 ("Body Protective Compound-157") is a synthetic peptide — a chain of 15 amino acids — based on a sequence identified in human gastric juice. It is marketed for tissue repair: healing of tendons, ligaments, muscle, and the gut lining. In animal research, the proposed mechanisms include:
- Upregulating VEGF (vascular endothelial growth factor), which promotes new blood-vessel formation and may speed tissue healing
- Modulating nitric oxide pathways involved in blood flow and vascular protection
- Modulating inflammatory pathways in preclinical experiments
| Commonly promoted use | Where the evidence stands |
|---|---|
| Tendon / ligament / muscle healing | Preclinical findings; no established controlled human evidence for these uses |
| Gut healing (ulcers, IBD, 'leaky gut') | Older placebo-controlled enema studies reported in meeting abstracts; limited reporting |
| Post-injury / post-surgery recovery | Anecdotal in humans; not established in controlled trials |
| Systemic 'anti-inflammatory' / longevity | Mechanistic hypothesis only — not demonstrated in humans |
The Evidence: Animal vs Human
The evidence is limited, but “no human research” is too absolute. FDA’s July 2026 review identified five clinical studies, including two older studies reported in meeting abstracts and three small uncontrolled reports.
| Evidence | What it can tell us |
|---|---|
| Older placebo-controlled enema studies | Phase 1 and ulcerative-colitis meeting abstracts exist; limited reporting prevents treating them as a complete efficacy and safety record |
| Knee-pain chart review | 17 patients identified; no randomized control group, so improvement cannot establish treatment effect |
| Other small pilots | Different routes and populations; not validation of common subcutaneous recovery regimens |
| Long-term safety | Not established by small, short studies |
What Commercial Interest Can and Cannot Tell Us
A possible expansion of eligible compounding substances can attract commercial interest. It does not establish that a company will sell BPC-157, how much revenue it might earn or when a product would become available. This article does not use share-price movement or analyst projections as evidence of medical benefit or regulatory approval.
Doses Circulating in the Community (No Clinical Validation)
An online vial’s label does not establish what was studied, what it contains or how it should be administered. For a persistent injury, the useful next step is diagnosis and discussion of treatments with evidence for that condition, not conversion of an animal experiment into a personal schedule.
Grey-Market Safety Risks
FDA’s review raises concerns about substance identity, impurities and immune responses. Its adverse-event review included reports after injectable BPC-157, including a combination product, but incomplete reporting and other ingredients limit causal conclusions. These reports do not establish an incidence rate.
“Research use only” does not establish quality or safety for injection. Suspected adverse events can be reported to FDA’s MedWatch program; it is incorrect to say there is no reporting mechanism.
BPC-157 vs TB-500
The two peptides are almost always mentioned together (the "BPC/TB blend"), and both were on the July 2026 PCAC docket. A quick orientation:
| BPC-157 | TB-500 (thymosin beta-4 fragment) | |
|---|---|---|
| Marketed for | Gut and tissue healing | Systemic soft-tissue recovery, flexibility |
| Controlled human evidence | Older enema-trial abstracts; no established recovery regimen | No clinical study of the exact fragment identified by FDA |
| 503A vote (Jul 2026) | Recommended 8–6 | Reviewed in the same session |
| FDA-approved? | No | No |
| Commonly stacked? | Yes, with TB-500 | Yes, with BPC-157 |
How This Relates to GLP-1 Drugs and Retatrutide
- The same 503A compounding pathway now being debated for BPC-157 is the one that made compounded semaglutide widely available.
- Combining BPC-157 with a GLP-1 medicine does not inherit the approved medicine's evidence or establish a treatment for joint or digestive symptoms.
- The regulatory pathways differ: retatrutide was not on the July agenda, and FDA says it cannot be used in compounding under federal law — see Are Peptides Legal in 2026? and the retatrutide FDA timeline.
Critically: unlike BPC-157, retatrutide's evidence comes from large published Phase 2 and Phase 3 trials. Claims for either substance should be judged against the same standards of clinical evidence; the available evidence is very different.
Frequently Asked Questions
Did the FDA approve BPC-157?
No. The July recommendation was advisory and did not approve a drug or add BPC-157 to the final 503A Bulks List. The current linked Category 1 document does not list it. There is no verified 12–24-month decision timetable in the sources used here.
Is BPC-157 legal now?
BPC-157 is not FDA-approved, and the July vote did not create a new legal supply pathway by itself. Its exact compounding status must be checked against current FDA rules and policies; a prescription or a research-use label is not sufficient proof.
Will Hims sell BPC-157?
This review does not establish a commercial launch plan for BPC-157 from Hims & Hers. A possible FDA list addition is not a company commitment or approval of a finished product.
What is the correct dose of BPC-157?
There is no validated dose for the injury-recovery use promoted online. The small human reports and older enema studies do not establish a general subcutaneous regimen or a safe combination with TB-500.
Is grey-market BPC-157 safe?
Safety is not established. FDA identified limitations in substance characterization and concerns involving impurities and immune reactions. Reported adverse events are signals to investigate, not proof of an incidence rate or which ingredient caused a reaction.
Could BPC-157 make cancer worse?
The available clinical evidence does not establish long-term cancer safety. FDA’s review also found no adequate studies to determine carcinogenic potential. Angiogenesis experiments are not proof that BPC-157 either causes or prevents cancer, and a screening test cannot turn an unvalidated treatment into a proven safe one.
What is the difference between BPC-157 and TB-500?
BPC-157 is promoted mainly for gut and tissue healing; TB-500 (a thymosin beta-4 fragment) is promoted for broader soft-tissue recovery. They are frequently stacked together as a "BPC/TB blend." BPC-157 has older randomized enema-study abstracts with limited reporting; FDA found no clinical studies of the exact TB-500 fragment. Neither is FDA-approved, and both were reviewed by PCAC in July 2026. Combining two unapproved peptides increases the unknowns.
Does BPC-157 help with weight loss?
The reviewed human evidence does not establish BPC-157 as a weight-loss treatment. Marketing it for recovery or combining it with another medicine does not demonstrate a metabolic benefit.
What other peptides did the FDA review in July 2026?
BPC-157 was the first of seven peptides on the July 23–24, 2026 PCAC docket. KPV (an anti-inflammatory peptide) passed the same 8–6 vote on the first day. Others reviewed in the session included TB-500 and MOTS-c, plus Semax, Epitalon, and DSIP. Each is voted on separately, and each recommendation is separate from a final list addition or drug approval.
Sources
-
FDA. BPC-157 scientific briefing, July 2026.
-
Lee and Padgett. Knee-pain chart review, 2021.
-
RAPS. Contemporaneous vote report, July 23, 2026.
-
U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
-
ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list (July 2026).
-
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 list). FDA.gov
-
Related on this site: Are Peptides Legal in 2026? · Grey-Market Peptides · Retatrutide Cost & Access · Retatrutide FDA Timeline
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
TB-500: FDA Review, Legality & Human Evidence
TB-500 is not FDA approved. The FDA review found no human effectiveness evidence; the reported committee vote remains unverified.
The Wolverine Stack: BPC-157 + TB-500
No established clinical evidence for the marketed recovery combination. Peptide identity, FDA status and unresolved safety questions.
Are Peptides Legal in 2026? Inside the FDA 503A Vote Result
FDA advisory votes do not add peptides to the final compounding list. Current U.S. rules, evidence limits and GLP-1 distinctions.
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Research labels and purity claims do not establish product equivalence, approved dosing or legal exemptions.
Retatrutide Cost per Month and How to Access It
Every legitimate route to retatrutide today, open trials updated daily, Lilly's expanded access criteria, and what it may cost once approved.